GET DAILY SIGNALSWhy Is Guardant Health (GH) Stock Down 5.31% Today?
Key Takeaways
- GH shares were down roughly 5.31% in Friday's session, trading near $145 after closing at $153.43 the prior day.
- The decline followed the company's third-quarter 2026 results, released after Thursday's close, which beat revenue and earnings estimates but raised full-year free cash flow burn guidance.
- Investors focused on the company's increased spending outlook of $205 million to $220 million in 2026 free cash burn, up from a prior $195 million to $205 million.
- Strong fundamentals — revenue up 36% year over year and Shield screening volume surging — were overshadowed by concerns about the cost of commercial scaling.
- The move ran counter to a broadly positive market, with the Nasdaq and S&P 500 trading higher while precision-oncology peers also fell after earnings.
- Traders are now watching the company's path to profitability and whether Shield's scaling can lower cash burn in 2027.
- For deeper analysis, explore Price Targets, Earnings, and Forecast data for GH.
- Discover top-performing automated strategies on the Trending AI Robots page.
Opening Summary
Guardant Health (GH), a precision-oncology company that develops blood-based liquid biopsy tests and data analytics for cancer care, saw its shares decline about 5.31% during Friday's session, trading near $145.29 compared with a prior close of $153.43. The move extended an after-hours selloff that began Thursday evening after the company reported third-quarter 2026 results. Although the quarter beat top- and bottom-line expectations, markets reacted negatively to an upward revision in the company's full-year free cash flow burn guidance, signaling that the cost of building out its commercial infrastructure will be higher than previously anticipated.
Earnings Results and Cash Burn Guidance
The primary catalyst behind the stock's decline was Guardant Health's third-quarter report. Revenue rose 36% year over year to $361 million, topping the consensus estimate of roughly $351 million, while the non-GAAP net loss of $0.29 per share came in better than expected. Despite these beats, investors keyed in on the company's revised cash-flow outlook. Management raised full-year 2026 free cash flow burn guidance to between $205 million and $220 million, up from a prior range of $195 million to $205 million. The bigger spending outlook signaled a longer and more expensive path to profitability, prompting a recalibration of near-term expectations.
Revenue Guidance Met, But Did Not Exceed
Guardant Health also raised its full-year 2026 revenue guidance to between $1.36 billion and $1.37 billion, up from a prior range, representing growth of roughly 38% to 40%. However, the midpoint of the new range aligned closely with analyst consensus, offering limited incremental upside. With shares having already rallied substantially over the prior year — trading within a 52-week range of $74.55 to $191.05 — the in-line revenue outlook left little room for the market to reward the stock, contributing to the earnings-driven selloff.
Operating Expenses and Growth Spending
Underlying the wider cash burn forecast was a meaningful increase in operating expenses. Non-GAAP operating costs climbed as the company expanded commercial infrastructure and marketing activities to support growth across its Screening and Oncology segments, alongside higher stock-based compensation. While Shield screening revenue surged 180% to $67.6 million and Oncology test volume grew 58%, the heavier spending profile weighed on sentiment as investors weighed the pace and cost of scaling against near-term profitability.
Market Context and Trading Activity
The decline in GH occurred against a generally constructive backdrop, with the Nasdaq and S&P 500 advancing during the session, underscoring that the move was driven by company-specific concerns rather than broad market weakness. The selloff also reflected pressure across the blood-testing and liquid-biopsy group, where peers such as Natera (NTRA) also fell sharply following their own quarterly reports. Trading volume in GH was elevated relative to its recent average, consistent with heavy repositioning after the earnings release.
What Comes Next for GH
Looking ahead, investors will monitor whether Guardant Health's Shield screening franchise can continue to scale efficiently and bring down its cost per test, which already improved during the quarter. Key watchpoints include the pace of payer coverage expansion, oncology pricing dynamics, and whether the company can narrow free cash flow burn as it approaches its targeted profitability timeline. The company's pipeline of regulatory milestones — including pending approvals and product launches — also remains a focal point. Risks include continued operating-expense growth, reimbursement uncertainty, and the dilution associated with stock-based compensation, all of which could keep pressure on shares even as top-line growth remains robust.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of automated bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to explore systematic approaches to the market. To see which strategies are currently leading, visit Trending AI Robots today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GH in downward trend: price dove below 50-day moving average on November 04, 2026
GH moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 23 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In 71 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for GH crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 244 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 189 of 210 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-90.844) is normal, around the industry mean (65.710). P/E Ratio (-42.983) is within average values for comparable stocks, (4.185). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Are the Contribution Limits For My Thrift Savings Plan?
What are the various methods for evaluating stocks in stock analysis?
NVO, UBER, DIS, APP, DASH, CVNA, TM, MCHP, SHOP, TTD, MGYOY | Q1 2025 Earnings Preview: May 7-9, 2025
Best RIP Theme Stocks for Investment
FAQ: How can I arrange a session with an expert to learn more about AI Robots?
General Information
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties
Advertisement